Does TAGRAXOFUSP-ERZS Cause Neoplasm recurrence? 14 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 14 reports of Neoplasm recurrence have been filed in association with TAGRAXOFUSP-ERZS. This represents 3.2% of all adverse event reports for TAGRAXOFUSP-ERZS.
14
Reports of Neoplasm recurrence with TAGRAXOFUSP-ERZS
3.2%
of all TAGRAXOFUSP-ERZS reports
9
Deaths
2
Hospitalizations
How Dangerous Is Neoplasm recurrence From TAGRAXOFUSP-ERZS?
Of the 14 reports, 9 (64.3%) resulted in death, 2 (14.3%) required hospitalization.
Is Neoplasm recurrence Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for TAGRAXOFUSP-ERZS. However, 14 reports have been filed with the FAERS database.
What Other Side Effects Does TAGRAXOFUSP-ERZS Cause?
Capillary leak syndrome (110)
Pyrexia (45)
Death (36)
Disease progression (33)
Thrombocytopenia (26)
Blood albumin decreased (24)
Acute kidney injury (23)
Off label use (23)
Weight increased (22)
Transaminases increased (21)
What Other Drugs Cause Neoplasm recurrence?
CYCLOPHOSPHAMIDE (293)
PALBOCICLIB (248)
DOXORUBICIN (240)
VINCRISTINE (239)
CYTARABINE (223)
METHOTREXATE (198)
CARBOPLATIN (170)
RITUXIMAB (163)
ETOPOSIDE (156)
PREDNISONE (144)
Which TAGRAXOFUSP-ERZS Alternatives Have Lower Neoplasm recurrence Risk?
TAGRAXOFUSP-ERZS vs TAHOR
TAGRAXOFUSP-ERZS vs TALAZOPARIB
TAGRAXOFUSP-ERZS vs TALC
TAGRAXOFUSP-ERZS vs TALIGLUCERASE ALFA
TAGRAXOFUSP-ERZS vs TALIMOGENE LAHERPAREPVEC